|
ACCESSWIRE TORONTO, ON / ACCESSWIRE / January 8, 2021 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 4,095,157 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the "Warrants"). The Warrants were issued on January 9, 2019 pursuant to a private placement involving the issuance of 4,095,157 units of the Company. The Company proposes to extend the expiry date of the Warrants that remain outstanding from the original expiry date of January 9, 2021 to January 9, 2023. All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the TSX Venture Exchange. About Theralase® Technologies Inc.Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses. Additional information is available at www.theralase.com and www.sedar.com |